Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:PFSCF OTCMKTS:SOAN OTCMKTS:TBUFF NASDAQ:VIRI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/ASOANAngioSoma$0.00$0.00▼$0.09$32.57M-0.466.74 million shsN/ATBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsVIRIVirios Therapeutics$4.90$4.86$0.13▼$1.04$94.36M1.581.05 million shs6,508 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%SOANAngioSoma0.00%0.00%0.00%0.00%-60.00%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%VIRIVirios Therapeutics0.00%-1.21%+0.20%-0.61%+2,652.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumePFSCFProMetic Life Sciences$5.47$5.47$5.47▼$352.00$127.45M2.46279 shsN/ASOANAngioSoma$0.00$0.00▼$0.09$32.57M-0.466.74 million shsN/ATBUFFTribute Pharmaceuticals Canada$0.00$0.50▼$1.86$105.76MN/A71,826 shs50,100 shsVIRIVirios Therapeutics$4.90$4.86$0.13▼$1.04$94.36M1.581.05 million shs6,508 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformancePFSCFProMetic Life Sciences0.00%0.00%0.00%0.00%0.00%SOANAngioSoma0.00%0.00%0.00%0.00%-60.00%TBUFFTribute Pharmaceuticals Canada0.00%0.00%0.00%0.00%0.00%VIRIVirios Therapeutics0.00%-1.21%+0.20%-0.61%+2,652.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PricePFSCFProMetic Life Sciences 0.00N/AN/AN/ASOANAngioSoma 0.00N/AN/AN/ATBUFFTribute Pharmaceuticals Canada 0.00N/AN/AN/AVIRIVirios Therapeutics 2.00Hold$5.002.04% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookPFSCFProMetic Life Sciences$36.55M3.49N/AN/A($67.63) per share-0.08SOANAngioSomaN/AN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DatePFSCFProMetic Life Sciences-$150.73MN/A0.00∞N/A-894.02%-3,350.55%-67.76%N/ASOANAngioSoma-$540KN/A0.00N/AN/AN/AN/A-1,245.34%N/ATBUFFTribute Pharmaceuticals CanadaN/AN/A0.00N/AN/AN/AN/AN/AN/AVIRIVirios Therapeutics-$5.30M-$0.27N/AN/AN/AN/A-130.33%-115.00%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthPFSCFProMetic Life SciencesN/AN/AN/AN/AN/ASOANAngioSomaN/AN/AN/AN/AN/ATBUFFTribute Pharmaceuticals CanadaN/AN/AN/AN/AN/AVIRIVirios TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioPFSCFProMetic Life SciencesN/A0.950.71SOANAngioSomaN/A0.290.29TBUFFTribute Pharmaceuticals CanadaN/AN/AN/AVIRIVirios TherapeuticsN/A7.277.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipPFSCFProMetic Life Sciences0.10%SOANAngioSoma0.02%TBUFFTribute Pharmaceuticals CanadaN/AVIRIVirios Therapeutics9.05%Insider OwnershipCompanyInsider OwnershipPFSCFProMetic Life SciencesN/ASOANAngioSomaN/ATBUFFTribute Pharmaceuticals CanadaN/AVIRIVirios Therapeutics12.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionablePFSCFProMetic Life Sciences5023.31 millionN/ANot OptionableSOANAngioSomaN/A476.83 millionN/ANot OptionableTBUFFTribute Pharmaceuticals CanadaN/A113.72 millionN/ANot OptionableVIRIVirios Therapeutics519.26 million16.91 millionOptionableSOAN, PFSCF, TBUFF, and VIRI HeadlinesRecent News About These CompaniesVirios Therapeutics (NASDAQ:VIRI) Trading 3.1% Higher - Here's What HappenedSeptember 1, 2025 | marketbeat.comVirios Therapeutics (NASDAQ:VIRI) Trading Up 0.1% - What's Next?August 9, 2025 | marketbeat.comDigital acceptance and commitment therapy for fibromyalgia – Authors' replyJune 13, 2025 | thelancet.comTDogwood Therapeutics Inc (DWTX)March 16, 2025 | investing.comDogwood prices 578,950 shares at $8.26 in registered direct offeringMarch 13, 2025 | markets.businessinsider.comDogwood announces conversion of existing $19.5M in debt to equityMarch 12, 2025 | markets.businessinsider.comDWTX Stock trading resumesFebruary 11, 2025 | markets.businessinsider.comDogwood Therapeutics, Inc. (DWTX)February 2, 2025 | finance.yahoo.comDWTX Stock trading halted, volatility trading pauseJanuary 28, 2025 | markets.businessinsider.comDWTX Stock Hits 52-Week High at $15.74 Amidst Strong Yearly GrowthJanuary 23, 2025 | msn.comDogwood announces first patient dosed in Phase 2b trial on HalneuronJanuary 21, 2025 | markets.businessinsider.comPolluted communities hold their breath as companies struggle with California’s diesel truck banDecember 10, 2024 | apnews.comADogwood Therapeutics faces potential Nasdaq delistingNovember 23, 2024 | uk.investing.comDogwood says low-dose IMC-2 treatment reduces long-COVID fatigueNovember 18, 2024 | markets.businessinsider.comDogwood Study Finds IMC-2 Treatment Reduces Long-COVID Related Fatigue, Sleep DisturbanceNovember 18, 2024 | markets.businessinsider.comInovio Pharmaceuticals (NASDAQ:INO) Stock Quotes, Forecast and News SummaryNovember 16, 2024 | benzinga.comDWTX: Phase 2 Long COVID Results Expected SoonNovember 12, 2024 | msn.comBuy Rating for Dogwood Therapeutics: Strategic Initiatives and Promising Pipeline Drive Analyst ConfidenceNovember 10, 2024 | markets.businessinsider.comDogwood Therapeutics Reports Q3 2024 Financial ResultsNovember 9, 2024 | markets.businessinsider.comDogwood Therapeutics Announces Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comDogwood Therapeutics, Inc.: Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementOctober 31, 2024 | finanznachrichten.deMedia Sentiment Over TimeSOAN, PFSCF, TBUFF, and VIRI Company DescriptionsProMetic Life Sciences OTCMKTS:PFSCF$5.47 0.00 (0.00%) As of 11/18/2019Prometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.AngioSoma OTCMKTS:SOANAngioSoma, Inc., a wellness company, engages in the development and commercialization of dietary supplements to the medical, wellness, and adult-use markets. The company was founded in 2016 and is based in Houston, Texas.Tribute Pharmaceuticals Canada OTCMKTS:TBUFFTribute Pharmaceuticals Canada Inc., formerly Stellar Pharmaceuticals Inc., is a Canadian pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada. The Company targets several therapeutic areas in Canada but has a particular interest in products for the treatment of pain, urology, dermatology and endocrinology/cardiology. It also sells Uracyst and NeoVisc internationally through a number of strategic partnerships. On December 1, 2011, it acquired 100% of Tribute Pharmaceuticals Canada Ltd. and Tribute Pharma Canada Inc. As of December 31, 2011, its portfolio of assets includes nine products: NeoVisc, NeoVisc Single Dose, Uracyst, BladderChek, Bezalip SR, Soriatane, Cambia, Daraprim, and MycoVa. It has licensed BladderChek for the Canadian market from Inverness Medical Innovations North America, Inc. It eveloped Uracyst, a sterile 2 % sodium chondroitin sulfate solution available in a 20 milliliter vial.Virios Therapeutics NASDAQ:VIRI$4.90 0.00 (0.00%) As of 09/8/2025Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 What August Labor Data Means for the S&P 500 in September Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
